ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech
ERYTECH Pharma announced its participation in HealthTech Innovation Days (HTID) organized by France Biotech on October 4 & 5, 2021.
The CEO Gil Beyen and CFO Eric Soyer will engage in one-on-one investor meetings. The company focuses on developing innovative therapies via encapsulating drugs in red blood cells, with its lead product eryaspase targeting cancer metabolism. Eryaspase is in Phase 3 trials for second-line pancreatic cancer and Phase 2 trials for triple-negative breast cancer. ERYTECH is listed on NASDAQ and Euronext under ticker ERYP.
- None.
- None.
ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech
Cambridge, MA (U.S.) and Lyon (France), September 28, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the company’s participation in one-on-one investor meetings at the HealthTech Innovation Days (HTID) by France Biotech being held in Paris and virtually on October 4th & 5th, 2021.
1x1 Meetings – October 4th & 5th
Gil Beyen, Chief Executive Officer and Eric Soyer, Chief Financial Officer will participate in virtual one-on-one meetings on October 4th & 5th, 2021.
For more information about the HealthTech Innovation Days, please visit https://htfc-eu.com/htid/
About ERYTECH and eryaspase
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.
The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in a Phase 3 clinical development for the treatment of second-line pancreatic cancer, which is fully enrolled and expected to read out top-line results in Q4 2021, and in an ongoing Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial (IST) in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.
Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer and treatment of acute lymphoblastic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase). The FDA and the European Medicines Agency have granted eryaspase orphan
drug status for the treatment of pancreatic cancer and ALL. ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France,
and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
For more information, please visit www.erytech.com
CONTACTS
| ERYTECH Eric Soyer CFO & COO | LifeSci Advisors, LLC Corey Davis, Ph.D. Investor relations | NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations Nicolas Merigeau Media relations |
+33 4 78 74 44 38 investors@erytech.com | +1 (212) 915 2577 cdavis@lifesciadvisors.com | +33 1 44 71 94 94 erytech@newcap.eu |
Attachment
FAQ
What is ERYTECH Pharma participating in on October 4 and 5, 2021?
Who will represent ERYTECH Pharma at the HTID event?
What is the primary focus of ERYTECH Pharma's research?
What is the status of ERYTECH's lead product, eryaspase?
On which stock exchanges is ERYTECH Pharma listed?
